White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome

被引:17
|
作者
Kim, Haesook T. [1 ]
Frederick, David [2 ]
Armand, Philippe [2 ]
Andler, Emily [2 ]
Kao, Grace [2 ]
Cutler, Corey [2 ]
Koreth, John [2 ]
Alyea, Edwin P., III [2 ]
Antin, Joseph H. [2 ]
Soiffer, Robert J. [2 ]
Ritz, Jerome [2 ]
Ho, Vincent T. [2 ]
机构
[1] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, Dept Hematol Oncol, Boston, MA 02215 USA
关键词
VERSUS-HOST-DISEASE; LYMPHOCYTE RECOVERY; MONOCYTE RECOVERY; BONE-MARROW; IMPACT; RISK;
D O I
10.1002/ajh.23695
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To determine whether outcome after allogeneic hematopoietic cell transplantation (HCT) could be estimated by using peripheral white blood cell count (WBC) as a metric that integrates several aspects of HCT recovery, we conducted a retrospective study of 1,109 adult patients who underwent first allogeneic HCT from 2003 through 2009. WBC at 1-3 months after HCT was categorized as low (<2), normal (2-10), and high (>10 x 10(9) cells/L). Overall survival (OS) and progression-free survival (PFS) were lower for patients with low or high WBC at 1-3 months after HCT (P<0.0001). We developed a predictive three-group risk model based on the pattern of WBC recovery early after HCT. Five-year OS was 47, 30, and 15% (P<0.0001) and 5-year PFS was 39, 22, and 14% for patients in the three different risk groups (P<0.0001). The pattern of WBC recovery early after HCT provides prognostic information for relapse, nonrelapse mortality, progression-free survival, and overall survival. A scoring system based on the trajectory of the WBC in the first 3 months after HCT can effectively stratify patients into three groups with different PFS and OS. If validated, this system could be useful in the clinical management of patients after HCT, and to stratify patients enrolled on HCT clinical trials. Am. J. Hematol. 89:591-597, 2014. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:591 / 597
页数:7
相关论文
共 50 条
  • [21] Novel Biomarkers for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation
    Chen, Sophia
    Zeiser, Robert
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [22] Clinical course of autologous recovery with chromosomal abnormalities after allogeneic hematopoietic stem cell transplantation
    Kato, Motohiro
    Nakasone, Hideki
    Nakano, Nobuaki
    Fuji, Shigeo
    Shinohara, Akihito
    Yokoyama, Hisayuki
    Sakashita, Kazuo
    Hori, Tsukasa
    Takahashi, Satoshi
    Nara, Miho
    Kanda, Yoshinobu
    Mori, Takehiko
    Takita, Junko
    Kawaguchi, Hiroshi
    Kawakita, Toshiro
    Ichinohe, Tatsuo
    Fukuda, Takahiro
    Atsuta, Yoshiko
    Ogata, Masao
    BONE MARROW TRANSPLANTATION, 2020, 55 (06) : 1023 - 1028
  • [23] Cerebrovascular disease after allogeneic hematopoietic stem cell transplantation: incidence, risk, and clinical outcome
    Lin, Ting-An
    Gau, Jyh-Pyng
    Liu, Yao-Chung
    Ko, Po-Shen
    Wang, Hao-Yuan
    Chien, Sheng-Hsuan
    Liu, Chia-Jen
    Hsiao, Liang-Tsai
    Chiou, Tzeon-Jye
    Liu, Jin-Hwang
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (05) : 584 - 592
  • [24] Cerebrovascular disease after allogeneic hematopoietic stem cell transplantation: incidence, risk, and clinical outcome
    Ting-An Lin
    Jyh-Pyng Gau
    Yao-Chung Liu
    Po-Shen Ko
    Hao-Yuan Wang
    Sheng-Hsuan Chien
    Chia-Jen Liu
    Liang-Tsai Hsiao
    Tzeon-Jye Chiou
    Jin-Hwang Liu
    International Journal of Hematology, 2019, 109 : 584 - 592
  • [25] Engraftment Syndrome after Allogeneic Hematopoietic Cell Transplantation Predicts Poor Outcomes
    Chang, Lawrence
    Frame, David
    Braun, Thomas
    Gatza, Erin
    Hanauer, David A.
    Zhao, Shuang
    Magenau, John M.
    Schultz, Kathryn
    Tokala, Hemasri
    Ferrara, James L. M.
    Levine, John E.
    Reddy, Pavan
    Paczesny, Sophie
    Choi, Sung Won
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (09) : 1407 - 1417
  • [26] EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation
    Sanchez-Escamilla, Miriam
    Flynn, Jessica
    Devlin, Sean
    Maloy, Molly
    Fatmi, Samira A.
    Tomas, Ana Alarcon
    Escribano-Serrat, Silvia
    Ponce, Doris
    Sauter, Craig S.
    Giralt, Sergio A.
    Scordo, Michael
    Perales, Miguel-Angel
    BONE MARROW TRANSPLANTATION, 2023, 58 (05) : 498 - 505
  • [27] EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation
    Miriam Sanchez-Escamilla
    Jessica Flynn
    Sean Devlin
    Molly Maloy
    Samira A. Fatmi
    Ana Alarcon Tomas
    Silvia Escribano-Serrat
    Doris Ponce
    Craig S. Sauter
    Sergio A. Giralt
    Michael Scordo
    Miguel-Angel Perales
    Bone Marrow Transplantation, 2023, 58 : 498 - 505
  • [28] Early recovery of naive T cells predicts improved survival after allogeneic hematopoietic stem cell transplantation
    Garcia de Soria, Valle Gomez
    Portero Sainz, Itxaso
    Perez Garcia, Yaiza
    Iturrate Basaran, Isabel
    Vega Piris, Lorena
    Ramirez Mengibar, Ana
    Lopez Huete, Victor
    Munoz Calleja, Cecilia
    BONE MARROW TRANSPLANTATION, 2019, 54 : 484 - 484
  • [29] Impact of Red Blood Cell and Platelet Transfusions at Early after Engraftment on Outcome of Allogeneic Hematopoietic Stem Cell Transplantation
    Ikeda, Kazuhiko
    Mashimo, Yumiko
    Ohkawara, Hiroshi
    Takahashi, Hiroshi
    Shichishima-Nakamura, Akiko
    Harada, Kayo Shirado
    Furukawa, Miki
    Noji, Hideyoshi
    Ogawa, Kazuei
    Ohto, Hitoshi
    Takeishi, Yasuchika
    BLOOD, 2014, 124 (21)
  • [30] Clinical Effects of Tacrolimus Blood Concentrations Early after Allogeneic Hematopoietic Stem Cell Transplantation
    Kubo, Hiroyuki
    Imataki, Osamu
    Fukumoto, Tetsuya
    Ishida, Tomoya
    Kubo, Yukiko Hamasaki
    Yoshida, Shunsuke
    Uchida, Shumpei
    Uemura, Makiko
    Fujita, Haruyuki
    Kadowaki, Norimitsu
    BLOOD, 2023, 142